# MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

> **NCT02364713** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 17 (actual)

## Conditions studied

- Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Ovarian Carcinosarcoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Primary Peritoneal Carcinosarcoma
- Primary Peritoneal Clear Cell Adenocarcinoma
- Primary Peritoneal Endometrioid Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Primary Peritoneal Transitional Cell Carcinoma
- Primary Peritoneal Undifferentiated Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- **DRUG:** Paclitaxel
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Topotecan Hydrochloride

## Key facts

- **NCT ID:** NCT02364713
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-13
- **Primary completion:** 2022-01-13
- **Final completion:** 2022-01-13
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364713, "MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02364713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*